Use of Aprotinin Therapy in a Patient with Factor V Leiden
- 1 March 1997
- journal article
- case report
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 84 (3) , 694-698
- https://doi.org/10.1097/00000539-199703000-00043
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Factor V Leiden and Risks of Recurrent Idiopathic Venous ThromboembolismCirculation, 1995
- World distribution of factor V LeidenThe Lancet, 1995
- Factor V Leiden (FVQ 506) is common in a Brazilian populationAmerican Journal of Hematology, 1995
- AprotininDrugs, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Aprotinin in perspectiveThe Annals of Thoracic Surgery, 1993
- High-dose aprotinin therapy: A review of the first five years' experienceJournal of Cardiothoracic and Vascular Anesthesia, 1992
- Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purificationThrombosis Research, 1990
- Aprotinin (Trasylol) is a competitive inhibitor of activated protein CThrombosis Research, 1989
- EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERYThe Lancet, 1987